Mycobacterium immunogenum

This student page has not been curated.

1. Classification

Bacteria; Actinobacteria; Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacterium

Species: M. immunogenum (Taxonomy Browser, n.d.)

2. Description and significance

M. immunogenum is a fast growing, nontuberculous bacterium in the genus Mycobacterium (Kaur et al., 2019), whose cases have started to increase over the past decade. This tenacious taxon is found in soil, dust, water, and aerosols (Garcia-Zamora et al., 2017). M. immunogenum is the source of infections involving contaminated water and contaminated surgical materials (Wilson et al., 2001). M. immunogenum has been found to have an association with various human diseases such as cutaneous infection and keratitis (Garcia-Zamora et al., 2017; Sampaio et al., 2006. There is no effective M. immunogenum treatment, due to the resistance of the bacterium to a wide variety of antibiotics such as cefmetazole, ciprofloxacin, and doxycycline (Jaén-Luchoro et al., 2016; Wilson et al., 2001). M. immunogenum is a potential candidate for a vaccine against tuberculosis (Kaur et al., 2019).

3. Genome structure

The genome of M. immunogenum (strain CCUG 47286T) is 5,573,781 base pairs and has a Guanine-Cytosine content of 64.3%. The genome contains two separate ribosomal operons and 61 tRNA sequences (Jaén-Luchoro et al., 2016). Coding systems that were found in the bacteria included: 109 that are associated with disease and defense and 33 that are associated with antibiotic resistance. A total of 5.484 coding sequences are predicted in the sample (Jaén-Luchoro et al., 2016). Genomic comparisons with M. tuberculosis and M. bovis have shown that M. immunogenum carries less virulence genes than its counterparts. When compared, M. immunogenum lacks a mycobacterium virulence operons which code for Esat-6- proteins, specifically EsxL and EsxK (Kaur et al., 2019). Genomic similarities with M. tuberculosis has made M. immunogenum a possible vaccine candidate for tuberculosis infections. M. immunogenum shares specific genes for virulence and surface antigens such as Rv0200, which allows for the possibility of animals inoculated with M. immunogenum generating Memory T cells which can prevent an infection of M. tuberculosis. (Kaur et al., 2019).

4. Cell structure and metabolism

M. immunogenum is a Gram-positive curved bacillus that does not form spores or aerial hyphaes (Wilson et al., 2001). M. immunogenum usually has been found to contain plasmids (Wallace et al., 2002). When cultured, it usually has a rough appearance, although smooth forms have been observed as well (Wilson et al., 2001). M. immunogenum grows optimally around the temperatures of 30- 35°C with an upper temperature limit to growth of 45 °C (Wilson et al., 2001). M. immunogenum does not use carbon sources such as citrate, D-glucitol, i-myo-inositol, or D-mannitol (Wilson et al., 2001). M. immunogenum is usually present in used water-based metalworking fluids and can metabolize one or more of the degraded hydrocarbons and mycolic acids in used fluids (Wallace et al., 2002).

5. Ecology

M. immunogenum is found in soil, dust, water, and aerosols (Garcia-Zamora et al., 2017) as well as special niches such as water-based metalworking fluids, a type of industrial fluids for metal, surgical materials (Wallace et al., 2002) and distilled water (Wilson et al., 2001). However, the evolutionary explanation for the selective habitat of M. immunogenum is unknown (Wallace et al., 2002). M. immunogenum grows rapidly on glass, copper, and galvanized surfaces (Trafny et al., 2013). Growing on surfaces allows M. immunogenum to create biofilms that make it less susceptible to antimicrobial compounds used to disinfect metal removal fluid (Falkinham, 2009; Roussel et al., 2010). M. immunogenum is highly resistant to chlorine and disinfecting agents (2% alkaline glutaraldehyde and 8% formaldehyde) as well as antibiotics, including cefmetazole, ciprofloxacin, doxycycline, imipenem, sulfamethoxazole, and tobramycin (Wilson et al., 2001). These characteristics allow M. immunogenum to also inhabit water-purification systems such as hospital water systems, causing nosocomial pseudo-outbreaks. Nevertheless, M. immunogenum is susceptible to the antibiotics amikacin and clarithromycin, as well as 5% NaCl at 35°C (Wilson et al., 2001).

6. Pathology

There have only been a few reported cases of infection from M. immunogenum over the past decade. As environmental organisms, nontuberculous mycobacteria like M. immunogenum can be found in soil, dust, aerosols, and water (Garcia-Zamora et al., 2017). The main sources of infection for the reported cases were from metal-working fluids, contaminated water, and contaminated surgical materials like blades (Garcia-Zamora et al., 2017). Those who were infected with M. immunogenum commonly experienced fevers, headaches, hypotension, and visual impairment (Garcia-Zamora et al., 2017). However, a majority of cases presented themselves as cutaneous infections (Garcia-Zamora et al., 2017). Multiple case reports have described the appearance of leg ulcers and abdominal papules and pustules as a result of being exposed to contaminated water or soil containing M. immunogenum (Garcia-Zamora et al., 2017; Shedd, Edhegard & Lugo-Somolinos, 2010). One report specifically discusses lesions forming around a tattoo that the patient had recently gotten, where they found M. immunogenum in the pigment used in the tattoo process (Mitchell et al., 2009). M. immunogenum has been described as opportunistic, as it has been found to target immunocompromised individuals and cause skin diseases (Shedd, Edhegard & Lugo-Somolinos, 2010). While a majority of the cases involving M. immunogenum have presented themselves as cutaneous infections, there was also an outbreak of keratitis in Brazil, where M. immunogenum was reported to be the cause. In late 2003, 36 patients received LASIK eye surgery and five experienced symptoms of keratitis after the operation. After performing corneal scrapings, M. immunogenum was determined to have contaminated the surgical material used in the procedure (Sampaio et al., 2006). Eliminating M. immunogenum from the hospital water supplies has proved to be quite difficult, even with the use of chemicals and heat (Shedd, Edhegard & Lugo-Somolinos, 2010). Nevertheless, treatment for those infected is quite simple: once a diagnosis is, patients receive antibiotic treatment. In most cases, patients can be treated for a certain period of time with clarithromycin or amikacin, both of which are effective against M. immunogenum as measured in vitro (Garcia-Zamora et al., 2017). While patients make a full recovery while on clarithromycin or amikacin, the optimal treatment for M. immunogenum is still unknown.

7. Applications to biotechnology

M. immunogenum is studied as a potential candidate for a vaccine against tuberculosis, caused by a group of bacteria called the Mycobacterium tuberculosis. BCG (Bacillus Calmette–Guérin), the current vaccine, only protects against childhood tuberculosis and not the adult manifestation of the disease due to its inability to sustain the life of memory T cells (Kaur et al., 2019). In an effort to develop a novel vaccine that would also target the adult onset of tuberculosis, strain CD11_6 of M. immunogenum was further studied. Genomic analysis showed that M. immunogenum has fewer virulence factors, but is also able to increase the number of activated central and effector memory CD4 T cells when injected into patients (Kaur et al., 2019). These characteristics of M. immunogenum could possibly mitigate the impact tuberculosis would have on the lungs and the spleen, with an increased efficacy of the vaccine to protect against more than just childhood tuberculosis. However, there was no significant difference detected in the impact of tuberculosis between M. immunogenum and BCG immunized groups in the study described above.

8. Current Research

M. immunogenum was characterized in 2001, but has recently gained attention due to its antibiotic resistance and its ability to thrive in a hospital environment (Wilson et al., 2001). The vaccine against M. tuberculosis is not widely distributed in many countries due to the variable effectiveness of the vaccine. In 2019, a research group showed that the M. immunogenum vaccine demonstrated a significant increase in the amount of memory T cells generated and the reduction of M. tuberculosis in vaccinated animals (Kaur et al., 2019).

9. References

[1] [Falkinham, J. O. 2009. Effects of Biocides and Other Metal Removal Fluid Constituents on Mycobacterium Immunogenum. Applied and Environmental Microbiology, 75(7), 2057-2061. doi:10.1128/aem.02406-08.]

[2] [Fedrizzi, T., Meehan, C., Grottola, A. et al. 2017. Genomic characterization of Nontuberculous Mycobacteria. Sci Rep 7(45258), https://doi.org/10.1038/srep45258]

[3] [Garcia-Zamora, E., Sanz-Robles, H., Elosua-Gonzalez, M., Rodriguez-Vasquez, X., and Lopez-Estebaranz, JL. 2017. Cutaneous infection due to Mycobacterium immunogenum: an European case report and review of the literature. Dermatol Online, 23(10). doi:13030/qt9zg5r07t]

[4] [Jaén-Luchoro, D., Seguí, C., Aliaga-Lozano, F., Salvà-Serra, F., Busquets, A., Gomila, M., Bennasar-Figueras, A. 2016. Complete genome sequence of the Mycobacterium immunogenum type strain CCUG 47286. Genome Announcements 4(3), e00401-16. doi:10.1128/genomeA.00401-16]

[5] [Kaur, G., Chander, A. M., Kaur, G., Maurya, S. K., Nadeem, S., Kochhar, R., Mayilraj, S. 2019. A Genomic Analysis of Mycobacterium Immunogenum Strain CD11_6 and Its Potential Role in the Activation of T Cells against Mycobacterium Tuberculosis. BMC Microbiology, 19(64). doi:10.1186/s12866-019-1421-y]

[6] [Mitchell, C. B., Isenstein, A., Burkhart, C.N., Groben, P., and Morrell, D. S. 2009. Infection with Mycobacterium Immunogenum following a Tattoo. Journal of the American Academy of Dermatology, 64(5), 70-71. doi:10.1016/j.jaad.2009.12.037 Roussel, S., Rognon, B., Barrera, C., Reboux, G., Salamin, K., Grenouillet, F., Millon, L. 2010. Immuno-reactive Proteins from Mycobacterium Immunogenum Useful for Serodiagnosis of Metalworking Fluid Hypersensitivity Pneumonitis. International Journal of Medical Microbiology, 301(2), 150-56. doi: 10.1016/j.ijmm.2010.07.002 ]

[7] [Sampaio, J. L. M., Nassar Jr, D., De Freitas, D., Höfling-Lima, A. L., Miyashiro, K., Alberto, F. L., and Leão, S. C. 2006. An Outbreak of Keratitis Caused by Mycobacterium Immunogenum. Journal of Clinical Microbiology, 44(9), 3201-3207. doi:10.1128/JCM.00656-06 ]

[8] [Shedd, A. D., Edhegard, K. D., and Lugo-Somolinos, A. 2010. Mycobacterium immunogenum skin infections: two different presentations. International Journal of Dermatology, 49(8), 941-944. doi:10.1111/j.1365-4632.2009.04363.x ]

[9] [Taxonomy Browser. (n.d.). NCBI. Retrieved from https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi Trafny, E.A., Lewandowski, R., Zawistowska-Marciniak, I., and Stpiska, M. 2013. Use of MTT assay for determination of the biofilm formation capacity of microorganisms in metalworking fluids. World J Microbiol Biotechnol 29, 1635–1643. https://doi-org.ezproxy.bu.edu/10.1007/s11274-013-1326-0 ]

[10] [Wallace, R. J., Zhang, Y., Wilson, R. W., Mann, L., and Rossmoore, H. 2002. Presence of Single Genotype of the Newly Described Species Mycobacterium immunogenum in Industrial Metalworking Fluids Associated with Hypersensitivity Pneumonitis. Applied and Environmental Microbiology, 68(11), 5580-5584. doi:10.1128/AEM.68.11.5580-5584.2002 ]

[11] [Wilson, R. W., Steingrube, V. A., Böttger, E. C., Springer, B., Brown-Elliott, B. A., Vincent, V., Wallace Jr, R. W. 2001. Mycobacterium immunogenum sp. Nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks and contaminated metalworking fluids: an international cooperative study on mycobacterial taxonomy. International Journal of Systematic and Evolutionary Microbiology, 51(5), 1751-1764. doi:10.1099/00207713-51-5-1751 ]